Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Biotech
Axsome adds AZ asset through Avenue subsidiary acquisition
Axsome is after BAER-101, a phase 2 oral GABA receptor modulator that Avenue's Baergic Bio originally licensed from AstraZeneca in December 2019.
Darren Incorvaia
Nov 6, 2025 10:50am
UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data
Nov 6, 2025 10:00am
Registrar snaps up CMC Medical Devices to expand offerings
Nov 6, 2025 8:35am
Lilly links amylin drug to 20% weight loss, races to phase 3
Nov 6, 2025 8:20am
Dynavax pays Vaxart $30M for oral COVID-19 vaccine program
Nov 6, 2025 5:50am
Judge denies Pfizer’s bid to block Novo’s offer for Metsera
Nov 5, 2025 5:23pm
